Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10796	Companies
233357	Keywords
162019	Articles
124543	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 06/06/2024 at 13:00, 2 years 1 month ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Moderna's mRNA-3705 selected for FDA's START pilot program to address rare diseases. The investigational mRNA therapeutic aims to treat methylmalonic acidemia due to MUT deficiency with innovative mRNA platform

Moderna Rare Diseases MMA MRNA-3705 START Pilot Program
PRESS RELEASE

published on 06/03/2024 at 14:00, 2 years 2 months ago

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II
BRIEF

published on 05/31/2024 at 17:03, 2 years 2 months ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA

FDA Approval Moderna Vaccine RSV MRESVIA
PRESS RELEASE

published on 05/31/2024 at 16:58, 2 years 2 months ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation

FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF

published on 05/22/2024 at 13:05, 2 years 2 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
PRESS RELEASE

published on 05/22/2024 at 13:00, 2 years 2 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development

Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF

published on 05/13/2024 at 13:05, 2 years 2 months ago

Moderna Announces Participation in Key Investor Conferences

Investor Conferences Healthcare Financial Markets Moderna Webcasts
PRESS RELEASE

published on 05/13/2024 at 13:00, 2 years 2 months ago

Moderna to Present at Upcoming Conferences in May/June 2024
Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available

Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF

published on 05/02/2024 at 12:35, 2 years 3 months ago

Moderna Reports Q1 2024 Financial Performance and Strategic Progress

Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
PRESS RELEASE

published on 05/02/2024 at 12:30, 2 years 3 months ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula

Accesswire

Published on 08/01/2026 at 01:20, 2 days 18 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 18 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 19 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 2 days 19 hours ago

BioNxt Solutions Announces Option Grants
Published on 07/31/2026 at 23:20, 2 days 20 hours ago

Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 19:35, 24 minutes ago

Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing
Published on 08/03/2026 at 19:01, 59 minutes ago

EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care reports operating income excluding special items to be above market expectations in Q2 2026 and confirms its outlook for the financial year 2026
Published on 08/03/2026 at 18:35, 1 hour 25 minutes ago

Holding(s) in Company
Published on 08/03/2026 at 18:35, 1 hour 25 minutes ago

Holding(s) in Company
Published on 08/03/2026 at 18:35, 1 hour 25 minutes ago

Holding(s) in Company

Les Echos

Published on 08/03/2026 at 18:45, 1 hour 15 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 08/03/2026 at 18:00, 2 hours ago

H1 2026 revenue
Published on 08/03/2026 at 17:45, 2 hours 15 minutes ago

Monthly disclosure of the total number of shares and voting rights - July 2026
Published on 08/03/2026 at 17:45, 2 hours 15 minutes ago

Weekly share buyback
Published on 08/03/2026 at 17:40, 2 hours 20 minutes ago

Eiffage announces the end of exclusive negotiations with Atlas Arteria for the possible acquisition of the Warnow Tunnel concession in Rostock, Germany

View all LES ECHOS COMFI WIRE